On May 16, 2014, Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), reported unaudited first quarter fiscal year 2014 earnings, for the period ended March 31, 2014. For the year ended March 31, 2014, Skystar’s revenues were roughly $6.8 million as compared to revenues of $5.5 million for the three months ended March 31, 2013, an increase of $1.3 million or 23.5%. Overall increase in revenue was due to increase in manufacturing at the Company’s Huxian plant in combination with receiving product permits by the Ministry of Agriculture to manufacture select veterinary medications. Revenue from sales of our veterinary medications increased by $1.4 million or 40.6%, from $3.4 million for the three months ended March 31, 2013 to $4.8 million for the three months ended March 31, 2014. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), net profit margin is 24.70% and weekly performance is -4.48%. On last trading day company shares ended up $6.19. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), distance from 50-day simple moving average (SMA50) is 7.31%.
On May 19, 2014, Vision-Sciences, Inc. (NASDAQ:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R)technology, announced the launch of its next generation video bronchoscope and EndoSheath technology. Vision-Sciences, Inc. (NASDAQ:VSCI), fell 5.11% in last trading session and ended the day on $1.11. VSCI, Gross Margin is 33.10% and its return on assets is -66.20%. Vision-Sciences, Inc. (NASDAQ:VSCI), quarterly performance is -32.72%.
On June 02, 2014, Biocept Inc (NASDAQ:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), announced the launch of its estrogen receptor (ER) status testing on CTCs that will be performed at the Company’s CLIA-certified and CAP-accredited laboratory. Biocept Inc (NASDAQ:BIOC), shares moved down 7.72% in last trading session and was closed at $5.38, while trading in range of $5.01 – 5.93. Biocept Inc (NASDAQ:BIOC), year to date (YTD) performance is -42.77%.
Agile Therapeutics Inc (NASDAQ:AGRX), major shareholder Care Capital Iii Llc bought 500,000 shares of the company’s stock in a transaction that occurred on Thursday, May 29th. The shares were purchased at an average price of $6.00 per share, with a total value of $3,000,000.00. Agile Therapeutics Inc (NASDAQ:AGRX), ended the last trading day at $5.81. Company weekly volatility is calculated as 6.64% and price to cash ratio as 36.02. Agile Therapeutics Inc (NASDAQ:AGRX), showed a negative weekly performance of 2.19%.
Equities researchers at Roth Capital started coverage on shares of Concert Pharmaceuticals Inc (NYSE:JMPC), in a research report issued on Thursday. The firm set a “buy” rating and a $28.00 price target on the stock. Roth Capital’s price target indicates a potential upside of 216.74% from the company’s current price. Concert Pharmaceuticals Inc (NYSE:JMPC), net profit margin is -71.50% and weekly performance is -5.33%. On last trading day company shares ended up $25.35. Analysts mean target price for the company is $27.00. Concert Pharmaceuticals Inc (NYSE:JMPC), distance from 50-day simple moving average (SMA50) is -17.80%.